Display options
Cite
Tedesco AP, Martins JS, Nicolini-Panisson RD. Focal treatment of spasticity using botulinum toxin A in cerebral palsy cases of GMFCS level V: evaluation of adverse effects. Rev Bras Ortop. 2014;49(4):359-63doi: 10.1016/j.rboe.2014.04.022.
Tedesco, A. P., Martins, J. S., & Nicolini-Panisson, R. D. (2014). Focal treatment of spasticity using botulinum toxin A in cerebral palsy cases of GMFCS level V: evaluation of adverse effects. Revista brasileira de ortopedia, 49(4), 359-63. https://doi.org/10.1016/j.rboe.2014.04.022
Tedesco, Ana Paula, et al. "Focal treatment of spasticity using botulinum toxin A in cerebral palsy cases of GMFCS level V: evaluation of adverse effects." Revista brasileira de ortopedia vol. 49,4 (2014): 359-63. doi: https://doi.org/10.1016/j.rboe.2014.04.022
Tedesco AP, Martins JS, Nicolini-Panisson RD. Focal treatment of spasticity using botulinum toxin A in cerebral palsy cases of GMFCS level V: evaluation of adverse effects. Rev Bras Ortop. 2014 May 10;49(4):359-63. doi: 10.1016/j.rboe.2014.04.022. eCollection 2014. PMID: 26229827; PMCID: PMC4511629.
Copy Download .nbib Format: NLM
Share it on

Rev Bras Ortop. 2014 May 10;49(4):359-63. doi: 10.1016/j.rboe.2014.04.022. eCollection 2014.

Focal treatment of spasticity using botulinum toxin A in cerebral palsy cases of GMFCS level V: evaluation of adverse effects.

Revista brasileira de ortopedia

Ana Paula Tedesco, Juliana Saccol Martins, Renata D'Agostini Nicolini-Panisson

Affiliations

  1. Instituto de Neuro-Ortopedia, Caxias do Sul, RS, Brazil.

PMID: 26229827 PMCID: PMC4511629 DOI: 10.1016/j.rboe.2014.04.022

Abstract

OBJECTIVE: To report on the experience of injections of botulinum toxin A (BTA) in a series of patients with cerebral palsy of Gross Motor Function Classification System (GMFCS) level V.

METHODS: This was a retrospective case series study on 33 patients with cerebral palsy of GMFCS level V who received 89 sessions of BTA application (of which 84 were Botox(®) and five were other presentations), in which the basic aim was to look for adverse effects.

RESULTS: The mean number of application sessions per patient was three, and the mean age at the time of each injection was 4 + 6 years (range: 1.6-13 years). The muscles that most frequently received injections were the gastrocnemius, hamstrings, hip adductors, biceps brachii and finger flexors. The mean total dose was 193 U and the mean dose per weight was 12.5 U/kg. Only one patient received anesthesia for the injections and no sedation was used in any case. No local or systemic adverse effects were observed within the minimum follow-up of one month.

CONCLUSION: The absence of adverse effects in our series was probably related to the use of low doses and absence of sedation or anesthesia. According to our data, BTA can be safely used for patients with cerebral palsy of GMFCS level V, using low doses and preferably without sedation or anesthesia.

Keywords: Botulinum toxin; Cerebral palsy; Muscle spasticity

References

  1. J Paediatr Child Health. 2007 Jun;43(6):499-501 - PubMed
  2. Dev Med Child Neurol. 2010 Feb;52(2):139-44 - PubMed
  3. J Neurol Neurosurg Psychiatry. 1999 Jul;67(1):90-3 - PubMed
  4. Clinics (Sao Paulo). 2010 Jun;65(6):613-9 - PubMed
  5. Dev Med Child Neurol. 2011 Feb;53(2):125-30 - PubMed
  6. Rev Neurol. 2003 Sep 1-15;37(5):444-6 - PubMed
  7. Eur J Neurol. 2010 Aug;17 Suppl 2:9-37 - PubMed
  8. Clin Rehabil. 2009 May;23(5):394-407 - PubMed
  9. PM R. 2010 Apr;2(4):282-4 - PubMed
  10. J Am Acad Dermatol. 2005 Sep;53(3):407-15 - PubMed
  11. Clin Neuropharmacol. 2007 Sep-Oct;30(5):310-3 - PubMed
  12. Plast Surg Nurs. 2008 Jul-Sep;28(3):150-1 - PubMed
  13. Neurology. 1988 Nov;38(11):1780-3 - PubMed
  14. Dev Med Child Neurol. 2001 Apr;43(4):234-8 - PubMed

Publication Types